Navigation Links
Adams Respiratory Therapeutics and Lipocine Enter into License and Collaboration Agreement
Date:9/19/2007

Adams Seeks to Develop New Prescription Adult Cough Products Using

Lipocine's Proprietary Lip'ral(TM) Technologies

CHESTER, N.J. and SALT LAKE CITY, Sept. 19 /PRNewswire-FirstCall/ -- Adams Respiratory Therapeutics, Inc. (Nasdaq: ARxT) and Lipocine Inc., a privately- held, leading drug delivery company that uses clinically validated proprietary technologies to address key unmet drug delivery and therapeutics needs, today announced that they have entered into a license and collaboration agreement to develop new prescription adult cough products.

Commenting on the agreement, COO Robert D. Casale said, "This collaboration with Lipocine provides Adams with access to an additional proprietary platform technology and fits with our strategy of taking established compounds and adding increased functionality to create patent- protected, value-added products. The products developed through this collaboration could offer doctors a non-narcotic prescribing option to treat cough with an enhanced dosing regimen. In addition, these products will help Adams compete in the $1.1 billion prescription cough and cold market in the United States."

"Given the large and growing size of the respiratory market, and how patients can benefit from enhanced dosage forms and regimens, we are very pleased to partner with Adams, a company highly respected for its commercialization accomplishments," said Dr. Mahesh Patel, president and CEO of Lipocine Inc.

Lip'ral(TM) and Lip'ral(TM)-SSR are clinically proven oral delivery technologies for water insoluble drugs that improve absorption and can be extended to enable controlled release of insoluble drugs and drugs with pH- sensitive solubility. Multiple patents have been issued and are pending on these proprietary technologies.

Under the terms of the agreement, Adams receives an exclusive, royalty- bearing license from Lipocine to develop and market multiple prescription adult cough products in North America. Lipocine is responsible for completing the product development work and will be eligible to receive reimbursements and payments in exchange for completing certain pre-defined development milestones. Adams will be responsible for performing all aspects of clinical development, regulatory submission, manufacture and commercial operations. Financial terms of the deal are not being disclosed. Adams reconfirms that it expects diluted earnings per share in fiscal 2008 to be in the range of $1.55 to $1.75, as previously disclosed in an August 21, 2007 press release.

About Adams Respiratory Therapeutics, Inc.

Adams is a specialty pharmaceutical company focused on the late-stage development, commercialization and marketing of over-the-counter and prescription pharmaceuticals for the treatment of respiratory disorders.

About Lipocine Inc.

Lipocine Inc. is a pharmaceutical company leveraging its proprietary drug delivery technologies to commercialize innovative pharmaceutical products. Lipocine business objectives are to develop products with established drugs that have patient friendly attributes such as faster absorption, lower dose, fewer side effects, less frequent dosing, and no food effect.

Adams Respiratory Therapeutics Forward-Looking Statement

This press release contains certain "forward-looking" statements, including Adams' application of the Lip'ral(TM) technology to prescription cough products, Adams' competitiveness in the prescription cough and cold market and Adams' future financial performance. Such forward-looking statements can be identified by the words "could," "will" and similar expressions and are subject to risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. Factors that could cause actual results to differ materially include, among others: Adams' successful consummation of the license and collaboration agreement with Lipocine, Inc.; Adams' ability to expand its product portfolio in the prescription cough and cold market; Adams' ability to successfully utilize the Lip'ral(TM) and Lip'ral(TM)-SSR technologies to develop prescription cough products; the continued success of Adams' existing products and the successful commercialization of future products; Adams' ability to compete against other branded products and generic competition; the severity of the cough and cold season and other risk factors set forth Item 1A. Risk Factors in the Company's Annual Report on Form 10-K for the fiscal year ended June 30, 2007. Except to the extent required by applicable securities laws, Adams is not under any obligation to (and expressly disclaims any such obligation to) update its forward-looking statements, whether as a result of new information, future events, or otherwise. All statements contained in this press release are made only as of the date of this release.


'/>"/>
SOURCE Adams Respiratory Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Canadian firm buys Proventiv Therapeutics, makes ex-Bone Care exec CEO
2. NanoRite Innovation Center opens with small science, big promise
3. UW-Madison to receive $125M for bioenergy research center
4. WARF enters licensing agreements for stem cell products
5. Internet-enabled niche markets take center stage
6. Virent enters agreement with Shell Oil unit to make hydrogen with biomass
7. TomoTherapy opens technical training center
8. Stem cell and regenerative medicine center to aid education and commerce
9. Mega-Metro Center may go beyond Chicago and Wisconsin
10. Software company enters health space with RFID solutions on hold
11. Former Fiserv exec to enter Business Hall of Fame
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/9/2016)... (PRWEB) , ... February 08, 2016 , ... ... multilingual testing services, announced today the launch of its revamped and improved website. ... scalable language service solutions, the redesigned website will better communicate how the company ...
(Date:2/9/2016)... ... February 09, 2016 , ... The publishing industry ... Access publishing is one of the popular publication models that has received wider ... and 3000+ International Conferences across the globe, OMICS International is ...
(Date:2/9/2016)... and LONDON , February 9, 2016 ... bio tech replace paper and protect IP ... electronic laboratory notebook (ELN) will be rolled out in ... research and development (R&D) and protect valuable IP. Users will ... follow a specific researcher or experiment as part of the ...
(Date:2/8/2016)... 8, 2016 /PRNewswire/ - BIOREM Inc. (TSXV: BRM) ("Biorem" or ... finalists for clean technology companies in the TSX Venture 50 ... companies listed on the TSX Venture Exchange, in each of ... clean technology & life sciences, diversified industries and technology ... to return on investment, market cap growth, trading volume and ...
Breaking Biology Technology:
(Date:2/5/2016)... , Feb. 5, 2016 ... of the "Global Facial Recognition Market ... --> http://www.researchandmarkets.com/research/5kvw8m/global_facial ) has announced the ... Market 2016-2020" report to their offering. ... http://www.researchandmarkets.com/research/5kvw8m/global_facial ) has announced the addition of ...
(Date:2/3/2016)... India , February 3, 2016 ... the new market research report "Automated Fingerprint Identification System ... Search, Latent Search), Application (Banking & Finance, Government, Healthcare, ... published by MarketsandMarkets, the market is expected to be ... CAGR of 21.0% between 2015 and 2020. The transformation ...
(Date:2/2/2016)... 2016  BioMEMS devices deployed in hospitals ... medical screening and diagnostic applications, such as ... that facilitate and assure continuous monitoring without ... being bolstered through new opportunities offered by ... coupled with wireless connectivity and low power ...
Breaking Biology News(10 mins):